Research dossier
Clinical research on Vitamin B9
7 trials reviewed across 6 indications.
Strongest evidence
Neural tube defect prevention
Mechanism
Folate provides one-carbon units for purine and pyrimidine synthesis. Rapidly dividing embryonic neural tissue has unusually high folate demand during the first 28 days after conception — before most women know they are pregnant.
This is the strongest evidence in the entire supplement literature. Pooled trials show folic acid cuts neural tube defects by roughly 70% when started before conception and continued through the first 12 weeks. Every major health authority recommends 400–800 mcg/day for women who could become pregnant.
Timing is everything. Starting after a positive pregnancy test is too late — the neural tube closes by week 4. The recommendation is for all women of reproductive age, not just those actively trying.
Trials cited
MRC Vitamin Study — folic acid for NTD recurrence
positive · RCT
MRC Vitamin Study Research Group, 1991, Lancetn=1817Among women with a prior NTD pregnancy, 4 mg/day folic acid reduced recurrence by 72%. The trial was stopped early once results were clear. This is the foundational evidence behind global folic acid fortification policy.
Czeizel & Dudas — folic acid for first-occurrence NTDs
positive · RCT
Czeizel & Dudas, 1992, NEJMn=4156Among 4,156 women with no prior history of NTD pregnancy, the folic-acid-containing multivitamin group had zero NTDs vs six in the trace-element group. Established that folic acid prevents first occurrences, not just recurrences.
Cochrane review — periconceptional folate for birth-defect prevention
positive · Systematic review
De-Regil et al., 2015, Cochrane Database of Systematic Reviewsn=7391Pooled across 5 trials and 7,391 women, daily folic acid cut neural tube defects by roughly 70% (RR 0.31). Effect held across the dose range studied (360 mcg to 4 mg/day). The strongest evidence in the entire supplement-and-pregnancy literature.
Anemia and red blood cell formation
Mechanism
Folate is required for DNA synthesis in dividing cells. Deficiency impairs erythropoiesis and produces megaloblastic anemia — large, immature red blood cells that don't carry oxygen well.
Folate's role in preventing and treating megaloblastic anemia has been settled medical knowledge for over 70 years. Genuinely deficient people respond reliably. Treating non-deficient people for general fatigue does not.
Repletion in deficiency is meaningful. Routine supplementation in well-replete adults adds nothing. Testing serum folate or RBC folate before supplementing makes sense if symptoms suggest deficiency.
DNA synthesis and methylation
Mechanism
Folate is the carrier of one-carbon units required for nucleotide synthesis and for the methylation reactions that regulate gene expression. Every dividing cell in the body needs adequate folate.
The cellular biochemistry is unimpeachable — folate is non-negotiable for DNA replication and the methyl-donor pool. Whether supplemental folate above dietary intake produces measurable cellular benefit in non-deficient adults is a different question, and the answer is mostly no.
Repletion in deficiency restores normal cellular function. Mega-dosing past sufficiency does not stack additional benefit and may carry risk (see the Cole 2007 colorectal adenoma trial).
Homocysteine and cardiovascular events
Mechanism
Methylfolate donates a methyl group to convert homocysteine into methionine. Elevated homocysteine is associated with cardiovascular disease in observational data — but causation has not held up in trials.
Folic acid reliably lowers homocysteine. The problem: lowering it does not reduce heart attacks or cardiovascular death. HOPE-2 (5,522 patients, 5 years) and NORVIT (3,749 post-MI patients, 3.5 years) both failed their primary endpoints. HOPE-2 showed a small stroke reduction; NORVIT suggested possible harm. The homocysteine-as-causal-target hypothesis did not survive these trials.
Don't take high-dose folic acid for cardiovascular prevention. The trials say it doesn't work, and the colorectal adenoma data raises concerns about chronic supraphysiological dosing.
HOPE-2 — B vitamins for cardiovascular events
negative · RCT
Lonn et al., 2006, NEJMn=55225,522 high-risk adults took daily B vitamins for 5 years. Homocysteine dropped by 2.4 micromol/L. Major cardiovascular events did not. A modest stroke reduction (relative risk 0.75) was the lone signal — the primary composite endpoint failed.
NORVIT — B vitamins after heart attack
negative · RCT
Bonaa et al., 2006, NEJMn=3749Lowering homocysteine by ~28% in 3,749 post-heart-attack patients did not reduce recurrent events. The trial suggested possible harm in the combined-vitamin arm. The authors recommended against using B-vitamin therapy after a heart attack.
Cognitive function in older adults
Mechanism
Folate supports methylation of neurotransmitters including dopamine and serotonin. High homocysteine is associated with cognitive decline and dementia risk in observational cohorts.
FACIT (818 older adults, 3 years) showed modest cognitive improvements in adults with elevated homocysteine and normal B12 — done before Dutch food fortification. The effect was real but small and the population was specifically selected for elevated homocysteine. Not a general-purpose brain supplement.
Most relevant in older adults with documented elevated homocysteine. In well-fortified populations with normal status, no clear cognitive benefit has been replicated.
FACIT — folic acid for cognitive decline in older adults
positive · RCT
Durga et al., 2007, Lancetn=818In 818 older adults with elevated homocysteine, 3 years of 800 mcg/day folic acid produced modest improvements in memory and processing speed vs placebo, with a 26% reduction in plasma homocysteine.
Conducted in the Netherlands before mandatory folic acid fortification. Effect size was modest and replication in fortified populations is mixed.
Depression
Mechanism
Folate supports synthesis of serotonin, dopamine, and norepinephrine via methyl-donor pathways. Low folate status is associated with poorer response to antidepressants in some studies.
L-methylfolate has been studied as an adjunct to antidepressants, with mixed results. Standard folic acid as an antidepressant augmenter has failed in larger trials. The story is not 'folate fixes depression' — it's 'folate deficiency might worsen depression treatment response.' Useful context, not a treatment.
Most reasonable in adults with documented low folate status who aren't responding to first-line antidepressants. Not a standalone depression treatment.
Honest-evidence ledger — 1 trial that didn’t move the needle
Surfacing failed trials alongside the positive evidence. Leaving them out would be marketing, not science.
Aspirin/Folate Polyp Prevention Study — folic acid and colorectal adenomas
negative · RCT
Cole et al., 2007, JAMAn=10211,021 adults with prior colorectal adenomas got 1 mg/day folic acid or placebo. Folic acid did not reduce adenoma recurrence. Worse, the folic acid group trended higher on advanced and multiple adenomas. The clearest published signal that high-dose folic acid in adults with existing pre-cancerous lesions may make them worse.
4 forms of Vitamin B9 compared
Folic acid
High — well absorbed but requires MTHFR-mediated conversion to active 5-MTHF
Best forPregnancy NTD prevention, food fortification, general repletionThe synthetic form used in fortified flour and most prenatal vitamins. Every landmark trial that established folate's role in NTD prevention used folic acid, not methylfolate. It works. The MTHFR-variant concern is real biochemistry but its clinical relevance in healthy adults is overstated by the supplement industry.
Metafolin®, Quatrefolic®
L-methylfolate (5-MTHF)
High — bypasses MTHFR conversion, reaches active form directly
Best forMTHFR variant carriers, depression augmentation, prenatal alternative for those preferring active formsThe bioactive form. Crosses MTHFR-related conversion bottlenecks and avoids accumulation of unmetabolized folic acid. Reasonable for adults with diagnosed MTHFR variants or depression context. Important caveat: no clinical trial has shown 5-MTHF prevents neural tube defects — folic acid is the proven prenatal form.
Leucovorin
Folinic acid (5-formyl-THF)
High — used clinically as a methotrexate rescue agent
Best forPharmaceutical rescue therapy, niche supplement useA reduced folate one step before methylfolate in the metabolic pathway. Mainly a prescription drug, not a typical supplement choice.
Generic folate (food form)
Moderate — natural folate from leafy greens, legumes, liver
Best forDietary intakeHeat-sensitive. Cooking destroys 50–95% of natural folate in vegetables, which is why fortification was designed around the more stable folic acid.
Are you deficient? Symptoms, risk groups, lab tests
Outright folate deficiency is uncommon in countries with food fortification (US, Canada, much of Latin America). It remains common in unfortified countries and in adults with malabsorption, alcohol use disorder, or on folate-antagonist medications.
Common symptoms
- Megaloblastic anemia (large, immature red blood cells)
- Persistent fatigue and weakness
- Pale skin
- Mouth sores and a smooth, sore tongue (glossitis)
- Shortness of breath
- Heart palpitations
- Reduced appetite
- Mood changes including irritability or low mood
- Difficulty concentrating
- Elevated homocysteine on lab testing
Who is at risk
Women trying to conceive or in early pregnancy
Demand for one-carbon units rises sharply during embryonic neural-tube closure. Routine dietary intake rarely meets the 600 mcg/day pregnancy target.
Adults with alcohol use disorder
Alcohol impairs intestinal folate absorption and increases urinary excretion. One of the classic causes of clinical folate deficiency.
Adults with malabsorption disorders
Celiac disease, Crohn's disease, and bariatric surgery all reduce folate absorption from the upper small intestine.
e.g. methotrexate, trimethoprim, sulfasalazine, phenytoin, carbamazepine, valproic acid
Patients on folate-antagonist medications
These drugs interfere with folate metabolism either by inhibiting dihydrofolate reductase or by impairing absorption.
Adults with MTHFR genetic variants
Common variants (C677T, A1298C) reduce conversion of folic acid to active 5-MTHF. The clinical impact in well-fed adults is debated and often overstated, but homozygous carriers have measurably higher homocysteine.
Older adults
Lower dietary intake, polypharmacy, and reduced absorption efficiency increase risk. Coexisting B12 deficiency complicates interpretation.
Lab markers
Serum folate
Reflects recent dietary intake and can normalize quickly with even modest supplementation. Not a great marker of long-term status.
Better:RBC (red blood cell) folate, Plasma homocysteine
- Deficiency
- <3 ng/mL
- Borderline
- 3–5.9 ng/mL
- Normal
- ≥6 ng/mL
RBC folate
Reflects folate status over the prior 3–4 months — more stable than serum folate.
- Deficiency
- <140 ng/mL
- Optimal for NTD risk reduction
- ≥400 ng/mL (≥906 nmol/L)
Side effects and drug interactions
Side effects
Masking of B12 deficiency
Common · Above 1,000 mcg/day, especially in older adults
High-dose folic acid corrects the megaloblastic anemia of B12 deficiency without correcting the underlying B12 problem. Neurological damage from B12 deficiency continues unchecked. This is the most consequential folate-supplement risk.
Gentler:Test B12 before chronic high-dose folate, Use lower doses of folic acid in non-pregnant adults
Unmetabolized folic acid in plasma
Common · Above 400 mcg/day
Above ~400 mcg/day of folic acid, the dihydrofolate reductase enzyme saturates and unmetabolized folic acid appears in circulation. The long-term significance is debated. L-methylfolate avoids this entirely.
Worse with:folic acid
Gentler:l-methylfolate
GI upset
Uncommon · Variable; uncommon below 1,000 mcg/day
Nausea, abdominal cramping, or bloating at higher doses. Generally mild and dose-dependent.
Sleep disturbance, irritability
Uncommon
Reported anecdotally with high-dose methylfolate, particularly in adults with COMT variants who may handle methyl-donor loads differently.
Worse with:l-methylfolate
Possible promotion of pre-existing pre-cancerous lesions
Rare · Chronic dosing at or above 1 mg/day
The Cole 2007 trial (1 mg/day folic acid for 6 years) showed more advanced and multiple adenomas in adults with prior colorectal adenomas. This is the most concrete evidence for a chronic-high-dose risk.
Drug interactions
Reduces nutrient status
methotrexatetrimethoprimsulfasalazinephenytoincarbamazepinevalproic acidThese drugs antagonize folate metabolism or absorption. Folate supplementation is sometimes co-prescribed with methotrexate to reduce side effects, but timing matters and should be physician-directed.
Folate supplementation in the context of these medications should be coordinated with the prescriber, not self-managed.
Combined-effect risk
5-fluorouracil (5-FU) and capecitabineFolate enhances the cytotoxicity of 5-FU. This is therapeutic in cancer treatment but means folate supplementation can affect chemotherapy response.
Patients on 5-FU-based chemotherapy should not take folate supplements without oncologist input.
Other
levodopaMethyl-donor folate forms can theoretically affect levodopa metabolism via methylation pathways. Clinical relevance is debated.
Patients with Parkinson's disease on levodopa should discuss high-dose methylfolate with their neurologist before starting.
Other critical caveats
- Folic acid can mask vitamin B12 deficiency. Chronic high-dose folate corrects the anemia of B12 deficiency without addressing the neurological damage, which continues silently. Test B12 status before starting chronic folate above 1 mg/day, particularly in older adults.
- The cardiovascular hypothesis failed. HOPE-2 (2006) and NORVIT (2006) both showed that lowering homocysteine with B vitamins does not reduce heart attacks. Don't take folic acid for heart-disease prevention.
- Folic acid before and during early pregnancy is one of the best-evidenced preventive interventions in medicine. By the time most women know they're pregnant, the neural tube has already closed. Daily 400–800 mcg from before conception is the standard recommendation for any woman who could become pregnant.
- High-dose folic acid in adults with prior colorectal adenomas may worsen them. The Cole 2007 trial showed this clearly. Older adults with a colon cancer history should avoid mega-dose folic acid.
Frequently asked
What's the difference between folic acid and methylfolate?
Folic acid is the synthetic form added to fortified foods and most prenatal vitamins. The body converts it to the active methylfolate (5-MTHF) via the MTHFR enzyme. Methylfolate supplements are 5-MTHF directly — bypassing that conversion. Folic acid is what the trials proving NTD prevention used. Methylfolate is reasonable for adults with MTHFR variants, depression-augmentation use cases, or anyone wanting to avoid unmetabolized folic acid in circulation. For pregnancy NTD prevention specifically, folic acid has the trial evidence — methylfolate does not yet.How much folate should I take?
Adults: 400 mcg DFE/day from food and supplements combined. Women trying to conceive or in early pregnancy: 400–800 mcg/day starting at least one month before conception. Pregnant women: 600 mcg/day. The supplemental upper limit is 1,000 mcg/day of synthetic folic acid — that ceiling exists because higher doses can mask B12 deficiency.Will folate help me feel less tired?
If you're frankly deficient, yes — repletion of true folate deficiency restores red blood cell production and reverses anemia-related fatigue. If your folate status is normal, supplementation does not reliably increase energy. Population fortification has made overt folate deficiency rare in fortified countries.Is folate safe during pregnancy?
Yes — and it's one of the best-evidenced preventive interventions in medicine. The challenge is timing: the neural tube closes by week 4 of pregnancy, often before women know they're pregnant. Standard guidance is for any woman who could become pregnant to take 400–800 mcg/day of folic acid daily. Women with a prior NTD pregnancy are typically prescribed 4 mg/day under medical supervision.Does folate prevent heart disease?
Not according to the trials. Folic acid lowers homocysteine reliably, but the large randomized trials (HOPE-2, NORVIT, SEARCH) all failed to show that this translates into fewer heart attacks or cardiovascular deaths. There is a small possible signal for stroke reduction in HOPE-2, but the primary cardiovascular endpoints were null. Don't take folate for heart prevention.
References
- 01NIH Office of Dietary Supplements — Folate Health Professional Fact Sheet
- 02CDC — Folic Acid
- 03Cochrane — Folic acid supplements before conception and in early pregnancy
Last reviewed2026-05-07